注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
BeiGene Ltd是一家全球性生物技术公司。该公司专注于开发和商业化肿瘤药物,以改善治疗效果并扩大全球患者的可及性。该发了三种获批药物,包括用于治疗各种血癌的布鲁顿酪氨酸激酶(BTK)小分子抑制剂RUKINSA;tislelizumab,一种抗PD-1抗体免疫疗法,用于治疗各种实体瘤和血癌和pamiparib,PARP1和PARP2的选择性小分子抑制剂。它已获得在美国、中国、欧盟、英国、加拿大和澳大利亚销售BRUKINSA的批准。该公司已获得在中国市场分销约13种获批药品的权利。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Steven Young | - | 2021 | Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board |
Michael Qingqing Yi | - | - | Independent Non-Executive Director & Co-Chairman Advisory Committe |
Xiaodong Wang | 61 | 2010 | Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder |
Donald Wayne Glazer | 80 | 2013 | Independent Non-Executive Director |
Anthony C. Hooper | 69 | 2020 | Independent Non-Executive Director |
Michael J. Goller | 49 | 2015 | Independent Non-Executive Director & Member of the Scientific Advisory Committee |
Ranjeev Krishana | 50 | 2014 | Independent Lead Director |
Corazon Dating Sanders | 67 | 2020 | Independent Non-Executive Director & Member of Scientific Advisory Committee |
Olivier Brandicourt | 68 | 2024 | Independent Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核